Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

Nat Rev Cancer 2006 Aug;6(8):613-25

Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA.

Cancer immunotherapy has been predominantly focused on biologically based intervention strategies. However, recent advances in the understanding of tumour-host interactions at the molecular level have revealed targets that might be amenable to intervention with small-molecule inhibitors. In particular, key effectors of tumoral immune escape have been identified that contribute to a dominant toleragenic state that is suspected of limiting the successful implementation of treatment strategies that rely on boosting immune function. Within the context of the pathophysiology of cancer-associated immune tolerance, this Review delineates potential molecular targets for therapeutic intervention and the progress that has been made in developing small-molecule inhibitors.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc1929DOI Listing
August 2006

Publication Analysis

Top Keywords

small-molecule inhibitors
12
tumoral immune
8
immune tolerance
8
key effectors
4
inhibitors key
4
effectors tumoral
4
tolerance review
4
cancer-associated immune
4
escape identified
4
immune escape
4
intervention small-molecule
4
level revealed
4
delineates potential
4
rely boosting
4
revealed targets
4
targets amenable
4
identified contribute
4
amenable intervention
4
review delineates
4
contribute dominant
4

Altmetric Statistics

References

(Supplied by CrossRef)

F Balkwill et al.
Lancet 2001

LM Coussens et al.
Nature 2002

GP Dunn et al.
Nature Immunol. 2002

W Zou et al.
Nature Rev. Cancer 2005

SA Rosenberg et al.
Nature Med. 2004

AL Mellor et al.
Nature Rev. Immunol. 2004

DH Munn et al.
Science 1998

DH Munn et al.
J. Exp. Med. 1999

F Burke et al.
Int. J. Cancer 1995

Y Ozaki et al.
Proc. Natl Acad. Sci. USA 1988

C Uyttenhove et al.
Nature Med. 2003

Similar Publications